Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cizutamig in Refractory Seropositive Rheumatoid Arthritis
NCT06946199Phase 1Recruiting
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cizutamig in rheumatoid arthritis (RA). Primary endpoints: Incidence and severity of treatment-emergent adverse events at Month 12, Changes from baseline in vital signs at Month 12 and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
cizutamig
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06946199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946199.